Yazar "Demirci, Umut" için listeleme
-
Classic Kaposi's sarcoma: A review of 156 cases
Çetin, Bülent; Aktaş, Bilge; Bal, Öznur; Algın, Efnan; Akman, Tülay; Koral, Lokman; Kaplan, Mehmet Ali; Demirci, Umut; Uncu, Doğan; Özet, Ahmet (Elsevier Taiwan, 2018)Background: Kaposi's sarcoma (KS) is a reactive, multifocal, multicentric, angiogenic neoplastic proliferation that is thought to originate from endothelial cells that are infected with human herpesvirus-8 (HHV-8). This ... -
Clinical significance of lymph node ratio in locally advanced breast cancer molecular subtypes
Demircioğlu, Fatih; Demirci, Umut; Kılıç, Diclehan; Özkan, Seçil; Karahacıoğlu, Eray (Karger, 2013)Background: the ratio of metastatic to dissected lymph nodes (lymph node ratio; LNR) is a sensitive and superior prognostic factor for lymph node evaluation, but its relationship to cancer subtypes is unclear. Patients and ... -
Lymph node ratio assessment of brain metastasis in early breast cancer cases
Demircioğlu, Fatih; Demirci, Umut; Akmansu, Müge (Asian Pacific Organization for Cancer Prevention, 2013)Background: Ten to 30% of early breast cancer (EBC) patients develop brain metastasis (BM) during their follow-up. In this study, we aimed to evaluate importance of the lymph node ratio (LNR) in development of BM in EBC ... -
Pazopanib-induced hepatotoxicity in an experimental rat model
Çetin, Bülent; Yılmaz, Güldal Esendağlı; Armağan, Berkan; Afşar, Barış; Demirci, Umut; Gülbahar, Özlem; Gümüşsoy, Özge; Bilgetekin, İrem; Özet, Ahmet; Üner, Aytuğ (Karger, 2018)Pazopanib is an effective treatment for advanced renal cell carcinoma and soft tissue sarcoma. Besides classical adverse events of this drug class, hepatotoxicity has been described as a frequent side effect. the aim of ... -
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gümüşay, Özge; Bayram, Ertuğrul; Demirel, Burçin Çakan; Acar, Ömer; Aksoy, Sercan; Baytemur, Nazife Köse; Şahin, Elif; Çabuk, Devrim; Başaran, Gül; Paydaş, Semra; Yaren, Arzu; Güven, Deniz Can; Erdoğan, Atike Pınar; Demirci, Umut; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hızal, Mutlu; Gülbağcı, Mutlu; Paksoy, Nail; Davarcı, Sena Ece; Yılmaz, Funda; Doğan, Özlem; Orhan, Sibel Oyucu; Kayıkcıoğlu, Erkan; Aytaç, Ali; Keskinkılıç, Merve; Moçan, Eda Eylemer; Ünal, Ölçün Ümit; Aydın,Esra; Yücel, Hakan; Işık, Deniz; Eren, Önder; Uluç, Başak Oyan; Özçelik, Melike; Hacıbekiroğlu, İlhan; Aydıner, Adnan; Demir, Hacer; Öksüzoğlu, Berna; Çılbır, Ebru; Çubukçu, Erdem; Çetin, Bülent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yıldırım, Nilgün; Alkan, Ali; Selçukbiricik, Fatih; Aksoy, Asude; Karakaş, Yusuf; Özkanlı, Gülhan; Duman, Berna Bozkurt; Aydın, Dinçer; Dulgar, Özgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tuğba; Aykan, Musa Barış; İnal, Ali; İriağaç, Yakup; Kalkan, Nurhan Önal; Keser, Murat; Sakalar, Teoman; Menekşe, Serkan; Kut, Engin; Bilgin, Burak; Karaoğlanoğlu, Müge; Sunar, Veli; Özdemir, Özlem; Turhal, Nazım Serdar; Karadurmuş, Nuri; Yalçın, Bülent; Şendur, Mehmet Ali Nahit (Future Medicine Ltd, 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...
